Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 15/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 14/20 | 0.47 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632206 | 0.91 | KLKB1 (0.49) | KLKB1MAP4K1TNIK | |
| SCHEMBL17909770 | 0.89 | KLKB1 (0.46) | KLKB1MAP4K1MAOB | |
| SCHEMBL21632183 | 0.86 | KLKB1 (0.48) | KLKB1MAP4K1 | |
| SCHEMBL17909742 | 0.84 | KLKB1 (0.47) | KLKB1MAP4K1MBOAT4 | |
| SCHEMBL1569191 | 0.81 | FYN (0.48) | KLKB1MAP4K1MBOAT4GRM2MAOB | |
| SCHEMBL17447258 | 0.80 | KLKB1 (0.46) | KLKB1MAP4K1 | |
| SCHEMBL21632423 | 0.79 | KLKB1 (0.58) | KLKB1MAP4K1 | |
| SCHEMBL17909745 | 0.79 | KLKB1 (0.54) | KLKB1MAP4K1MBOAT4 | |
| SCHEMBL1568328 | 0.78 | MBOAT4 (0.44) | KLKB1MAP4K1MBOAT4GRM2MAOB | |
| SCHEMBL16880704 | 0.78 | KLKB1 (0.80) | KLKB1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885MBOAT4 4725/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885MBOAT4 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.